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Abstract 
Lung cancer being the most prevalent malignancy in men and the 3rd most frequent in women is still 
associated with dismal prognosis due to advanced disease at the time of diagnosis. Novel targeted 
therapies are already on the market and several others are under investigation. However 
non-specific cytotoxic agents still remain the cornerstone of treatment for many patients. Central 
airways stenosis or obstruction may often complicate and decrease quality of life and survival of 
these patients. Interventional pulmonology modalities (mainly debulking and stent placement) can 
alleviate symptoms related to airways stenosis and improve the quality of life of patients. Mito-
mycin C and sirolimus have been observed to assist a successful stent placement by reducing 
granuloma tissue formation. Additionally, these drugs enhance the normal tissue ability against 
cancer cell infiltration. In this mini review we will concentrate on mitomycin C and sirolimus and 
their use in stent placement. 
Key words: pharmacology, stents. 
Introduction 
Lung cancer still remains a difficult to treat can-
cer, since patients are diagnosed at late stage disease 
due to lack of symptoms.[1] Moreover; lung cancer is 
the second most lethal cancer after prostate for men 
and breast for women, with a trend to increase for 
women in the future.[1] Several medical societies are 
trying to identify those groups of patients that will 
benefit from imaging screening with several novel 
techniques.[2-4] Until now there is no algorithm for 
early diagnostic approach for lung cancer, and pa-
tients are usually investigated if symptoms appear. In 
the last decade several molecular pathways have been 
investigated and several novel drugs are already on 
the market for non-small cell lung cancer 
(NSCLC).[5-8] Regarding small cell lung cancer 
(SCLC) we still do not have novel therapies, however; 
 
Ivyspring  
International Publisher 
 Journal of Cancer 2016, Vol. 7 
 
http://www.jcancer.org 
378 
novel treatment approaches are investigated with the 
main concept of immunomodulation being the most 
feasible right now.[9-14] Side effects from non-specific 
cytotoxic agents are well known and there are several 
patients that have to postpone their treatment.[15, 16] 
Apart from the side effects induced by the chemo-
therapeutic agents, there are several situations where 
the tumor has infiltrated different parts of the airways 
and respiratory distress is observed.[17] Several tech-
niques can be used to open a closed central airway 
and chemotherapy or radiotherapy can be used to 
preserve the result.[18, 19] Debulking of cancer tissue 
is usually performed with different types of lasers, 
electrocautery, argon plasma coagulation (APC) or 
cryotherapy.[20] (Figures 1-2) In order to keep the 
airway opened we use additionally stent devices.[20, 
21] Ballon dilatation and photodynamic therapy 
(PDT) are other options with specific indications [22, 
23] There is also a classification system for airway 
stenosis that can be used by medical practitioners.[24] 
Stents have been used for tracheal and esophageal 
fistulas.[25, 26] For malignant airway stenosis we 
usually use self-expanding covered or uncovered 
stents. [21] In order to keep the good result of 
debulking cancer tissue we have to choose carefully 
the right time of debulking with systemic, intra-
tumoral [27,149] (or a combination of both modalities 
of) chemotherapy and / or radiotherapy. Moreover; it 
has been observed that different stents (diameter, 
length, materials) induce different local stress.[28] 
Furthermore stents induce locally stress to the sur-
rounding tissues. They increase proliferation of gran-
uloma tissue in benign airway stenosis and increase 
angiogenesis. Cancer tissue which already has in-
creased angiogenesis when more stress is applied 
locally shows further enhanced tissue formation.[29] 
Therefore novel cytokine eluting stents are being de-
veloped.[30] Furthermore, novel research of stent 
placement at least for the gastrointestinal tract has 
indicated that stent placement might induce cancer 
cell migration.[31] Several drugs have been used as 
adjuvant local application in order to preserve the 
airway passage.[30, 32-36] In this review we will focus 
on the drugs that have been used with stents, their 
pharmacological activity and future applications. 
Additionally, we will include studies with data ap-
plicable for lung cancer patients. 
Search strategy 
 We performed an electronic article search 
through PubMed, Google Scholar, Medscape and 
Scopus databases, using combinations of the follow-
ing keywords: mitomycin c, floxuridine, sirolimus, 
stents, lung cancer stents, dumon stents, zotarolimus, 
rapamycin, 5-fluorouracil, doxycycline, everolimus 
and pirfenidone. All types of articles (randomised 
controlled trials, clinical observational cohort studies, 
review articles, case reports) were included. Selected 
references from identified articles were searched for 
further consideration.  
 
 
Figure 1. From top left to right bottom, hole made from excision of paratracheal tumor and covered stent placement with balloon dilation. 
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Figure 2. Argon plasma debulking. 
 
Drug Pharmacology  
Cisplatin 
Cisplatin, is a well-known non-specific chemo-
therapy drug. It is one of the first member of a class of 
platinum-containing anti-cancer drugs. These days 
this group of drugs includes carboplatin, oxaliplatin 
and lipoplatin. These platinum complexes react in 
vivo, binding to and causing crosslinking of DNA, 
which finally induce apoptosis. Cisplatin is usually 
administered intravenously as short-term infusion in 
normal saline for treatment. It is used to treat 
(non-)small cell lung cancer, ovarian cancer, lym-
phomas, bladder cancer, cervical cancer, and germ 
cell tumors.[37] Cisplatin has been observed to be 
particularly effective against testicular cancer; the 
cure rate was improved from 10% to 85%.[38] 
Cisplatin is known to crosslink DNA in several 
different ways, interfering with cell division by mito-
sis. The damaged DNA elicits DNA repair mecha-
nisms, which in turn activate apoptosis. Most notable 
among the changes in DNA are the 1,2-intrastrand 
cross-links with purine bases. These include 
1,2-intrastrand d(GpG) adducts which form nearly 
90% of the adducts and the less common 
1,2-intrastrand d(ApG) adducts. 1,3-intrastrand 
d(GpXpG) adducts occur but are readily excised by 
the nucleotide excision repair (NER). Cisplatin has no 
alkyl group unable to carry out alkylating reactions. 
However; it is correctly classified as 
alkylating-like.[39, 40] Of note is the fact that different 
chemotherapeutic especially alkylating agents (like 
cyclophosphamide) play a specific role as causative 
for initiation / aggravation of (underlying) pulmo-
nary hypertension in cancer patients during specific 
cancer treatment.[27] Such a (by chemotherapy) in-
duced pulmonary hypertension is often classified as 
pulmonary veno-occlusive disease (PVOD) which 
resembles in many features a typical pulmonary arte-
rial hypertension but is accompanied with a much 
worse prognosis in comparison to e.g. an idiopathic 
pulmonary arterial hypertension. Furthermore the 
diagnosis of induced PVOD is even more difficult 
when other hemodynamic comorbidities like left 
heart disease is already existing on chemotherapy 
initiation. It is worth mentioning that the establish-
ment of the diagnosis of PVOD itself is very difficult 
and many times only possible post-mortal. In regards 
to real-life scenarios with underlying hemodynamic 
relevant comorbidities it is one of the most complex 
diagnosis in medicine in human beings alive. There-
fore we believe that this diagnosis may be under-
scored in cancer patients and could be a part of the 
explanation for the still worse prognosis in many solid 
cancers especially under treatment despite new, very 
expensive targeted therapies. It has to be mentioned 
that any reduction of cardiac output will increase the 
interstitial fluid pressure intratumorally which is 
linked to a worse efficacy of any cancer treatment. 
Cisplatin resistance 
Cisplatin combination chemotherapy is the cor-
nerstone treatment of many cancers. However; many 
cancer patients will eventually relapse with cispla-
tin-resistant disease. Mechanisms regarding the cis-
platin resistance have been proposed including 
changes in cellular uptake and efflux of the drug, in-
creased detoxification of the drug, inhibition of 
apoptosis and increased DNA repair.[41, 42] Oxali-
platin is active in highly cisplatin-resistant cancer cells 
in the laboratory but there is little evidence for its ac-
tivity in the clinical treatment of patients with cispla-
tin-resistant cancer. The drug paclitaxel may be useful 
in the treatment of cisplatin-resistant cancer; the 
mechanism for this activity is yet unknown.[43] In 
regards to hemodynamic properties of paclitaxel it is 
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of interest that this drug can influence the altitude of 
life limiting pulmonary hypertension positively via 
the Forkhead box O (FoxO) transcription factors 
which are key regulators of cellular proliferation. 
Using intravenous or inhaled paclitaxel will lead to 
pharmacological reconstitution of FoxO1 
transcription factor activity in pulmonary artery 
smooth muscle cells (PASMCs) which serves as a 
potential treatment option for pulmonary 
hypertension.[44] This detail my be of interest when 
discussing chemotherapy options in cancer patients 
with severe pulmonary hypertension beside cancer 
diagnosis especially in the situation of no or minor 
response to first line cisplatin. 
Fluorouracil 
Fluorouracil is a pyrimidine analog drug which 
is used in the treatment of cancer. It is a suicide in-
hibitor and works through irreversible inhibition of 
thymidylate synthase. This drug is an antimetabolite. 
5-Fluorouracil acts primarily as a thymidylate syn-
thase (TS) inhibitor. Its main action is to block the 
synthesis of the pyrimidine thymidine which is a nu-
cleoside required for DNA replication. Thymidylate 
synthase methylates deoxyuridine monophosphate 
(dUMP) in order to synthesize thymidine mono-
phosphate (dTMP). The administration of 5-FU in-
duces cell death via thymineless death.[45] Calcium 
folinate stabilises the 5-FU-TS complex and enhances 
5-FU's cytotoxicity.[46] There is very little difference 
between the minimum effective dose and maximum 
tolerated dose of 5-FU, and it has been observed that 
the drug exhibits individual pharmacokinetic varia-
bility.[47-49] Therefore, an identical dose of 5-FU may 
result in different therapeutic response between pa-
tients.[48] It has been observed that both overdosing 
and underdosing are of concern with 5-FU. Moreover; 
the majority of colorectal cancer patients treated with 
5-FU are underdosed based on today's dosing stand-
ard, body surface area (BSA).[50-53] The limitations of 
BSA-based dosing is an issue for many physicians as 
they cannot accurately titer the dosage of 5-FU for the 
majority of individual patients, which results in 
sub-optimal treatment efficacy or excessive 
toxicity.[51, 52] 
The dihydropyrimidine dehydrogenase (DPD) 
enzyme is responsible for the detoxifying metabolism 
of fluoropyrimidines, a class of drugs that includes 
5-fluorouracil, tegafur and capecitabine[54] Moreover; 
genetic variations within the DPD gene (DPYD) can 
lead to reduced or absent dihydropyrimidine dehy-
drogenase activity, and individuals who are hetero-
zygous or homozygous for these variations may have 
partial or complete DPD deficiency. It is estimated 
that about 0.2% of individuals have complete dihy-
dropyrimidine dehydrogenase deficiency.[54, 55] 
Those patients with partial or complete dihydropy-
rimidine dehydrogenase deficiency have increased 
risk of severe or even fatal drug toxicities when 
treated with fluoropyrimidines; such as; neurotoxici-
ty, myelosuppression.[55, 56]  
At least two studies have found significant rela-
tionships between concentrations of 5-FU in blood 
plasma and both desirable or undesirable effects on 
patients. [52, 56] Further evaluation of the drug is 
based on the concentration of 5-FU in plasma that can 
increase desirable outcomes while minimizing nega-
tive side effects of 5-FU therapy.[52, 56] Towards this 
direction a blood test has been created and is being 
used in some centers as My5-FU test.[53]  
Floxuridine 
Floxuridine is an antimetabolite. The drug is 
mostly used in the treatment of colorectal cancer. 
Floxuridine, an analog of 5-fluorouracil, is a fluori-
nated pyrimidine.  
Mitomycin C 
The mitomycins are a family of aziri-
dine-containing natural products isolated from Strep-
tomyces caespitosus or Streptomyces lavendulae. Mito-
mycin C (MTC, an antibiotic), finds use as a chemo-
therapeutic agent by virtue of its antitumour activity. 
It is applied intravenously to treat upper gas-
tro-intestinal cancers (e.g. esophageal carcinoma), 
breast cancers and anal cancers, moreover; in bladder 
instillation for superficial bladder tumours. It causes 
delayed bone marrow toxicity and therefore it is usu-
ally administered at 6-weekly intervals. Prolonged 
use may result in permanent bone-marrow damage. 
The usual adverse effects are lung fibrosis and renal 
damage. Mitomycin C has also been used topically 
rather than intravenously in several areas, like super-
ficial cancers, particularly bladder cancers and intra-
peritoneal tumours. It is now well known that a single 
instillation of this agent within 6 hours on bladder 
tumor resection can prevent recurrence. Mitomycin C 
is a potent DNA crosslinker. A single crosslink per 
genome has shown to be effective in killing bacteria. 
This is accomplished by reductive activation followed 
by two N-alkylations. Both alkylations are sequence 
specific for a guanine nucleoside in the sequence 
5'-CpG-3'.[57] Potential bis-alkylating heterocylic 
quinones were synthetised in order to explore their 
antitumoral activities by bioreductive alkylation.[58] 
Mitomycin is also used as a chemotherapeutic agent 
in glaucoma surgery.[59] In the study by Li Y. et al. 
[60] a novel combination of PEGylated phytosomes 
with mitomycin C has been constructed in order to 
enhance the efficacy of mitomycin C. PEG complex 
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has been observed in other studies that induces a 
``stealth`` activity for several chemotherapeutic sub-
stances and in this way it produces a release effect for 
many cytotoxic drugs.[61, 62] In the study by Moi-
seyenko VM. Et al. [63] it was observed that heavily 
pretreated ovarian cancer patients carrying germ-line 
BRCA1 mutation benefited from the administration of 
mitomycin C. This study provides evidence that sev-
eral molecular pathways of NSCLC should be inves-
tigated along with the local administration of mito-
mycin C (MTC). In regards to hemodynamic proper-
ties of this drug (especially in comparison to the above 
mentioned details for cisplatin and paclitaxel) it is of 
interest that MTC intravenous therapy is a potent 
inducer of PVOD in humans and for intraperitoneal 
MTC therapy in rats.[64] Amifostine prevents 
MTC-induced PVOD in rats and should be tested as a 
preventive therapy for MTC-induced PVOD in 
humans. 
Special Reference to 
Pirfenidone 
Pirfenidone is an anti-fibrotic drug which is 
currently used in the treatment of idiopathic pulmo-
nary fibrosis (IPF). It is known to reduce lung fibrosis 
through downregulation of the production of growth 
factors and procollagens I and II. Several studies have 
established its antifibrotic and anti-inflammatory 
properties in vitro systems and animal models of fi-
brosis.[65] A number of cell-based studies have 
shown that pirfenidone reduces fibroblast prolifera-
tion,[66-69] inhibits tumor Growth Factor-β (TNF-β) 
stimulated collagen production[70] and reduces the 
production of fibrogenic mediators such as TGF-β.[68] 
The drug has also shown to reduce production of in-
flammatory mediators such as tumor growth factor-α 
(TNF-α) and interleukin 1β (IL-1β) in both cultured 
cells and isolated human peripheral blood mononu-
clear cells.[71-74] These activities are consistent with 
the broader antifibrotic and anti-inflammatory activi-
ties observed in animal models of fibrosis and in vitro. 
[66, 69] 
Everolimus 
Everolimus is known to be a derivative of siro-
limus and is considered an inhibitor of mammalian 
target of rapamycin (mTOR). It is used as an immu-
nosuppressant to prevent rejection of organ trans-
plants and treatment of renal cell cancer and other 
tumors. Much research has also been conducted on 
everolimus and other mTOR inhibitors as a possible 
targeted therapy for use in several types of cancers. 
Like the others mTOR inhibitors its effect is solely on 
the mTORC1 protein complex and not on the 
mTORC2 complex. This function leads to a hy-
per-activation of the kinase AKT via inhibition on the 
mTORC1 negative feedback loop while not inhibiting 
the mTORC2 positive feedback to AKT. This AKT 
elevation can lead to longer survival in some cell 
types. Based on this activity everolimus has an im-
portant effect on cell growth, cell proliferation and cell 
survival. It has been observed that mTORC1 action is 
modulated by several mitogens, growth factors and 
nutrients. 
The two genes TSC1 and TSC2 (which are the 
genes involved in tuberous sclerosis disease) act as 
tumour suppressor genes by regulating mTORC1 
activity. Therefore the loss or inactivation of one of 
these genes leads to the activation of mTORC1.[75] 
Everolimus binds to its protein receptor FKBP12, 
which directly interacts with mTORC1 inhibiting its 
downstream signaling. As a consequence, mRNAs 
that codify proteins implicated in the cell cycle inhibit 
tumour growth.[75] 
Recent trials have indicated that adding Afinitor 
(everolimus) to exemestane therapy against advanced 
breast cancer can significantly improve progres-
sion-free survival compared with exemestane therapy 
alone.[76, 77] However, everolimus increased mortal-
ity in cancer patients in some studies.[77-79] 
Furthermore, there are two studies that show a 
different sensitivity to everolimus between patients 
depending on their genome.[79, 80] In a Phase II clin-
ical trial done in patients with advanced metastasic 
bladder carcinoma (NCT00805129)[80] they found one 
person that positively responded to everolimus 
treatment for 26 months. A genetic sequence was 
performed for this patient. It was discovered that 
mutations in TSC1 lead to an increase in recurrence 
and to an increase in the response time to everolimus. 
Therefore, it has been determined that everolimus is 
more efficient in those patients that present somatic 
mutations in TSC1.[81] 
Zotarolimus  
Zotarolimus is an immunosuppressant and is 
considered a semi-synthetic derivative of rapamycin. 
It was primarily designed for use in stents with 
phosphorylcholine as a carrier. It was observed that 
coronary stents reduce early complications and im-
prove late clinical outcomes in patients needing in-
terventional cardiology. However, complications 
have been observed with stent use, such as the de-
velopment of thrombosis which impedes the effi-
ciency of coronary stents. Moreover; haemorrhagic 
and restenosis complications are additional problems 
that can be observed. Therefore drug-eluting stents 
have been developed. Stents are bound by a mem-
brane consisting of polymers which releases zotaro-
limus slowly and its derivatives into the surrounding 
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tissues. Zotarolimus is an analog made by substitut-
ing a tetrazole ring in place of the native hydroxyl 
group at position 42 in rapamycin. The compound is 
extremely lipophilic, and therefore has limited water 
solubility. The poor water solubility prevents rapid 
release into the circulation (for coronary stents) since 
elution of drug from the stent will be partly dissolu-
tion rate-limited. The slow rate of release and subse-
quent diffusion of the molecule facilitates the 
maintenance of therapeutic drug levels eluting from 
the stent. However; the surrounding tissue has to be 
considered too. Moreover; its lipophilic property in-
duces crossing cell membranes to inhibit neointimal 
proliferation of target tissue. Zotarolimus is the most 
lipophilic of all drug eluting stents (DES) drugs.[82] 
Sirolimus 
Sirolimus (also known as rapamycin) is a chem-
ical that was discovered as a product of bacteria Siro-
limus, was originally developed as an antifungal 
agent. However, this use was abandoned when it was 
discovered to have potent immunosuppressive and 
antiproliferative properties. It has been shown to 
prolong the life of mice and might also be useful in the 
treatment of certain cancers. [83] Sirolimus is not a 
calcineurin inhibitor, but it has a similar suppressive 
effect on the immune system. Sirolimus inhibits in-
terleukin-2 (IL-2) and other cytokines recep-
tor-dependent signal transduction mechanisms, via 
action on mTOR, and thereby blocks the activation of 
T and B cells. It is known that tacrolimus and cyclo-
sporine inhibit the secretion of IL-2, by inhibiting cal-
cineurin. Sirolimus binds to the cytosolic protein 
FK-binding protein 12 (FKBP12) like tacrolimus. Un-
like the tacrolimus-FKBP12 complex, which inhibits 
calcineurin (PP2B), the sirolimus-FKBP12 complex 
inhibits the mTOR (mechanistic (formerly mammali-
an) target of Rapamycin. Rapamycin directly binds to 
mTOR Complex 1 (mTORC1). mTOR has also been 
called FRAP (FKBP-rapamycin-associated protein), 
RAPT1, RAFT (rapamycin and FKBP target). Siroli-
mus binds to FKBP12-sirolimus complex and inhibits 
Tor1 and Tor2. [84-86] There have been numerous 
studies with sirolimus-eluting stents used for coro-
nary disease.[87-91]. Sirolimus eluting stents have 
demonstrated that they can inhibit neointimal prolif-
eration when applied next to bare metal stents.[87, 92, 
93] Several groups have investigated different com-
binations of sirolimus and sustain release drugs in 
order to prolong the positive effect of the stent.[88, 89, 
94, 95] Several imaging methods have been also ap-
plied in order to evaluate sirolimus stent implantation 
in the coronary vessels. [91, 96, 97]In the study by 
Habib et. al. [98] it was observed that metformin im-
pairs vascular endothelial recovery after stent place-
ment in the setting of locally eluted mammalian target 
of rapamycin inhibitors. Metformin could therefore be 
administered as an adjuvant treatment for these pa-
tients or added in the eluting solution. The admin-
istration of granulocyte colony-stimulating factor has 
been observed to attenuate endothelial dysfunction 
after sirolimus eluting stent implantation.[99] In the 
study by Erdim et. al. [100] and Tarantini et. al. [101] 
there were a difference observed between paclitaxel 
eluting stents and sirolimus eluting stents. The same 
was true when sirolimus and paclitaxel eluting stents 
were compared to bare metal stents.[102] 
Paclitaxel 
Paclitaxel is used to treat a number of cancers 
such as; ovarian cancer, breast cancer, lung cancer and 
pancreatic cancer. Paclitaxel and docetaxel represent 
the taxane family of drugs. Paclitaxel's mechanism of 
action involves interference with the normal break-
down of microtubules during cell division. Its com-
mon side effects include: muscle and joint pains, hair 
loss, and diarrhea. Anaemia and infections can occur 
and can be potentially serious. It should not be used 
during pregnancy as it often results in problems in the 
infant. Paclitaxel is used as an antiproliferative agent 
for the prevention of restenosis (recurrent narrowing) 
of coronary and peripheral stents; locally delivered to 
the artery wall. It has been observed that paclitaxel 
coating limits the growth of neointima (scar tissue) 
within stents.[103] It is known that paclitaxel targets 
tubulin. Paclitaxel-treated cells have defects in mitotic 
spindle assembly, chromosome segregation, and cell 
division. Paclitaxel stabilizes the microtubule polymer 
and protects it from disassembly. Consequently 
chromosomes are unable to achieve a metaphase 
spindle configuration. This function blocks progres-
sion of mitosis, and prolonged activation of the mi-
totic checkpoint triggers apoptosis or reversion to the 
G-phase of the cell cycle without cell division. It has 
been observed that the ability of paclitaxel to inhibit 
spindle function is generally attributed to its sup-
pression of microtubule dynamics. Moreover; in vitro 
studies it has been observed that at higher therapeutic 
concentrations, paclitaxel appears to suppress micro-
tubule detachment from centrosomes. This process 
occurs during mitosis. Paclitaxel binds to beta-tubulin 
subunits of microtubules.[104-108] Paclitaxel eluting 
stents have been used for airway bypass [109] and for 
coronary vessel implantation.[100-102, 110-114] 
Paclitaxel solution has been also conjugated with a 
carrier in order to produce a sustain drug release ef-
fect.[115] 
Doxycline 
Doxycycline is a broad-spectrum antibiotic of the 
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tetracycline class that is useful for the treatment of 
many infections. Doxycycline–metal ion complexes 
are unstable at acid pH, therefore more doxycycline 
enters the duodenum for absorption while other ear-
lier tetracycline compounds are released in the upper 
gastrointestinal tract. Moreover; it was mentioned 
that food has less effect on absorption than on ab-
sorption of earlier drugs with doxycycline serum 
concentrations being reduced by about 20% by test 
meals compared with 50% for tetracycline.[116] Ex-
pired tetracyclines or tetracyclines allowed to stand at 
a pH less than 2 are reported to be nephrotoxic due to 
the formation of a degradation product, such as the 
hydro-4-epitetracycline which induces the Fanconi 
syndrome. It is known for doxycycline that the ab-
sence of a hydroxyl group in C-6 prevents the for-
mation of this nephrotoxic compound. Tetracyclines 
and doxycycline itself have to be taken with precau-
tion by patients with kidney injury, as they can 
worsen azotemia due to catabolic effects.[117] In the 
study by Huvenne W. et. al. [36] it was observed that 
doxycycline-releasing stents improved postoperative 
healing after functional endoscopic sinus surgery.  
Sirolimus vs. Everolimus 
In the study by Gao R. et. al. [94] novel abluminal 
groove-filled biodegradable polymer sirolimus elut-
ing stent was investigated versus a durable polymer 
everolimus-eluting stent: None of the two stents pre-
sented positive results after 12 months follow up and 
none was observed to be superior. Regarding the 
novel abluminal groove-filled biodegradable polymer 
sirolimus eluting stent the authors stated that the stent 
was not inferior to the everolimus stent. The stents 
were found to be effective mainly for the first nine 
months. In the study by Smits P. C. et. al. [118] ablu-
minal biodegradable polymer biolimus-eluting stents 
were tested versus durable polymer everolimus 
stents: This time the biolimus stents were found to be 
as effective as the everolimus stents. In the study by 
Harjai K. J. et. al. [110] it was observed that everoli-
mus eluting stents were more efficient when com-
pared to sirolimus and paclitaxel eluting stents at least 
for 3 months of follow up. Again in the study by Park 
K. W. et. al. [119] Kitabata H. et. al. [120], Moreno R. 
et. al. [121], Kozuma K. et. al. [122] and Ko Y-G. et. al. 
[97] everolimus eluting stents were found to be supe-
rior when compared to sirolimus eluting stents. 
Zotarolimus vs. Everolimus 
In the study by Tandjung K. et. al. [123] no dif-
ference was observed between the zotarolimus and 
everolimus stents in terms of safety and efficiency. 
However; in the study by Kim S. et. al. [124] although 
zotarolimus had rapid neointimal healing at 3 
months, the zotarolimus stents had a slightly better 
vascular healing profile at long term 12 months. In the 
study by Park K. W. et. al. [125] both zotarolimus and 
everolimus stents showed the same safety and effi-
ciency profile after 1 year follow-up. 
Zotarolimus vs. Paclitaxel  
In the study by Xu B. et. al. [126] It was observed 
that zotarolimus stents were more efficient when 
compared to paclitaxel eluting stents within 12 
months of follow up. 
Sirolimus vs. Zotarolimus 
In the study by Van den Branden B. et. al. [127] 
sirolimus eluting stents were found to have higher 
efficiency than zotarolimus stents. 
Stent Studies for the respiratory tract 
Cisplatin 
In the study by Chao YK et al. [35] biodegradable 
stents made of polycaprolactone were fabricated by a 
laboratory-made, microinjection molding machine. 
Initially, in vitro mechanical strength of the stents was 
compared with the strength of Ultraflex SEMSs. Pol-
ylactide-polyglycolide copolymer and cisplatin were 
coated onto the surfaces of the stents. Elution method 
and high-performance liquid chromatography 
(HPLC) analysis were used to examine the in vitro 
cisplatin release characteristics. In vivo, the stents 
were surgically implanted into the cervical trachea of 
white rabbits. Bronchoscopic examination was per-
formed weekly and Cisplatin concentrations in tra-
chea, lung, and blood were analyzed by HPLC. His-
tologic examination was also performed. The biode-
gradable stent exhibited mechanical strength compa-
rable to the strength of Ultraflex SEMSs and provided 
a steady release of cisplatin for 4 weeks in vitro. The in 
vivo study showed sustained cisplatin levels in rabbit 
trachea for 5 weeks with a minimum drug level in 
blood. Histologic examination showed an intact cili-
ated epithelium and marked leukocyte infiltration in 
the submucosa of the stented area.  
Mitomycin C 
In the study by Choomg C. K. et al. [128] mito-
mycin C (MTC) was administered locally after stent 
placement for airway bypass and blocked granuloma 
tissue formation for up to a week. In the study by 
Coppit G. et. al. [129] MTC failed to affect the acute 
inflammatory response, perhaps secondary to the 
robust inflammatory reaction created by combining a 
single-stage laryngotracheal reconstruction (SSLTR) 
with the local circumferential trauma induced by the 
Palmaz stent. This may have reduced the beneficial 
effects of the MTC in this study. However; incorpora-
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tion of the auricular cartilage graft the stent was im-
proved, contributing again to improved airway sta-
bility. The mechanism of this action is not yet under-
stood, as MTC is considered a potent fibroblast inhib-
itor and not a promoter of neochondrogenesis. It is 
possible that this is an effect of MTC not previously 
described. In the study by Sztano B. et. al. [130] mi-
tomycin C prolonged fibrotic tissue formation for al-
most 6 weeks in a young boy. On the other hand in the 
study by Uzomefuna V. et. al. [131] again it did not 
present a positive antiproliferative effect, however; 
the authors provide data where the effect might be 
associated with the patients’ age. In the study by 
Carter J. M. et. al. [132] the positive application of 
MTC was observed with fewer days of hospitaliza-
tion. In another study by Kim H. et. al. [133] investi-
gating again the effect of MTC application in congen-
ital choanal atresia as in the study by Carter J. M. et. 
al. [132] no positive effect was observed in this group. 
In the study by Cardoso P.F.G. et.al. [109] paclitaxel 
eluting stents were used for airway bypass. Initial 
results indicated reduction of hyperinflation and im-
proved pulmonary function and dyspnea. In the 
study by Choong C.K. et. al. [134] in an animal model 
prolongation of patency was observed. However; in 
the study by Shah P.L. et. al. [135] no benefit was ob-
served from these stents for homogenous emphyse-
ma. Although a previous study by the same group 
implicated that these patients might benefit from 
these stents.[136] In the study by Zhu G. H. et. al. [137] 
bioabsorbable tubular stents eluting MTC (tracheal) 
were created and they were found to be superior to 
silicone stents. This study is very important because it 
provides data regarding the importance of the stent 
design in mucus trapping. The authors propose a 
stent design along with a drug eluting carrier, how-
ever; further investigation is needed for the stent de-
sign. 
Doxycycline 
In the study by Huvenne W. et. al. [36] doxycy-
cline drug eluting stents were designed and applied 
for sinus surgery. It was observed that matrix metal-
loproteinase-(MMP-9) levels were lower along with 
bacterial colonization and additionally short time 
healing was observed. 
Carriers designed for coronary, airway 
and gastrointestinal stents 
In the study by Bang S. et. al. [138] paclitax-
el-eluting membranes were designed in order to re-
lease paclitaxel: Positive results have been observed 
for more than 15 days after implantation. In the study 
by Qiu H. et. al. [88] sirolimus bioabsorable 
poly-L-lactic acid stents were designed and were ef-
fective up to 28 days. In the study by Deng J. et. al. 
[89] a nanoporous CREG-sirolimus eluting stent was 
designed with positive effects between 2-4 weeks. In 
the study by Christiansen E. H. et. al. [139] a bioli-
mus-eluting biodegradable polymer-coated stent was 
compared to durable polymer-coated siroli-
mus-eluting stent, however; after 1 year the results 
did not indicate a superiority of these novel stents. In 
the study by Gao R. et. al. [94] novel abluminal 
groove-filled biodegradable polymer sirolimus elut-
ing stent was investigated versus a durable polymer 
everolimus-eluting stent: None of the two stents pre-
sented positive results after 12 months follow up and 
none was observed to be superior from one another. 
In the study by Huvenne W. et. al. [36] a doxycycline 
eluting stent was created from copolymer blocks. It 
was observed that matrix metalloproteinase-(MMP-9) 
levels were lower along with bacterial colonization 
and additionally short time healing was observed. In 
the study by Chao Y. et. al. [35] polylac-
tide-polyglycolide copolymer-cisplatin stents were 
designed and a sustainable release was observed for 
up to 5 weeks. In the study by Lemos P. et. al. [140] 
using polymer-free phospholipid encapsulated siro-
limus nanocarriers stents the drug transfer was feasi-
ble to all layers of the vessel wall, achieving high tis-
sue concentration that persisted days after the appli-
cation. In the study by Seo J-B. et. al. [113] two dif-
ferent types of paclitaxel eluting stents were investi-
gated: The polymer polysulfone (Coroflex) and pol-
ymer ``Translute`` (Taxus). The Taxus stent was ob-
served to be superior to the Coroflex within a 9 month 
follow up.  
Discussion 
The inherent growth inhibitory properties of 
many anti-cancer agents make these drugs ideal can-
didates for the prevention of restenosis. However, 
these same properties are often associated with local 
cytotoxicity such as; fistulas. Therefore a multimodal-
ity approach is necessary either with debulking and 
then stent placement or radiotherapy when appro-
priate. Performance status, comorbidities, disease 
extend and anatomical malformations of the patient 
should be considered.  
Preparation is necessary in many cases as airway 
malformation is observed and therefore 3 dimensional 
investigation has been proposed.[141] In the study by 
Ratnovsky A. et. al. [28] the stress of different materi-
als were investigated and the authors proposed a pa-
tient-specific trachea model evaluation before stenting 
the patient. The method of stent application/stress, 
different material and different tissue (be-
nign/malignant) could probably be assessed one day 
for each patient before application in order to avoid 
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adverse effects. Since MTC is an antitumour drug that 
is used in both benign and malignant tissue formation 
after stent placement, we suggest that other cytotoxic 
agents with or without carrier that modulate the re-
lease of the drug locally should be investigated.[57] 
Regarding pirfenidone, we cannot propose further 
studies when we have tissue formation around the 
edge of a stent if the underlying disease is cancer, 
however; it would be interesting to design 
pirfenidone eluting stents for benign obstructions. In 
the study by Barone-Rochette G. et. al. [142] data are 
presented where current technology of drug eluting 
stents is cost effective and therefore novel stents 
should be encouraged. An issue to be investigated is 
whether we should provide the patients with an ad-
juvant therapy when implanting an airway stent. 
There is the case of the immunosuppressant rapamy-
cin which was the basis for the development of zo-
tarolimus by Johnson and Johnson. Rapamycin was 
originally approved for the prevention of renal trans-
plant rejection in 1999. There is evidence for coronary 
stents that when metformin is administered impair-
ment of vascular endothelial recovery is observed. 
More studies should be performed towards this di-
rection. Another issue is the adverse effects of the 
drugs that are conjugated with the stent. There is a 
case reported where a zotarolimus eluting stent in-
duced hypersensitivity pneumonitis.[143] In the study 
by Iwata Y. et. al. [99] granulocyte colony-stimulating 
factor was administered and it was observed that 
endothelial dysfunction was attenuated after siroli-
mus eluting stents implantation. Again in the study 
by Rhew S. H. et. al. [144] repeated catastrophic mul-
ti-vessel coronary spam was observed after zotaroli-
mus-eluting stent. In the study by Zhu G. H. et. al. 
[137] bioabsorbable tubular tracheal stents eluting 
MTC were created and found to be superior to sili-
cone stents. This study is very important because it 
provides data regarding the importance of the stent 
design in mucus trapping. The authors propose a 
stent design along with a drug eluting carrier, how-
ever; further investigation is needed for the stent de-
sign. 5- fluorouracil (5-FU) nitinol stents have been 
used for the gastrointestinal tract, and could be inves-
tigated for the respiratory tract.[145] There are cur-
rently novel methods for evaluating the concentration 
of paclitaxel and 5-FU simultaneously [146], moreo-
ver; novel ampiphilic copolymers have been designed 
to control the drug release such as; 5-FU.[146-148] 
(Figure 3, Tables 1-2) 
In our mini review we investigate the current 
knowledge from the coronary drug eluting stents and 
we present also a comparison between the different 
materials. We are trying to create a bridge between 
this knowledge and the data that we obtained from 
eluting airway stent techniques. There has not been 
much effort towards stents for lung cancer patients. 
The main reason is that patients usually have a low 
performance status when stents are applied usually as 
palliative treatment. Moreover; interventional pul-
monology has many tools for rapid local control. 
However; a long term local therapy through airway 
stents for these patients is welcomed. Going through 
the literature we believe that an ideal airway stent 
should (1) possess sufficient strength to perform its 
mechanical function, (2) be biocompatible so that the 
material breakdown process will not cause any tissue 
irritation, (3) be biodegradable (no need for removal 
after serving its purpose), and/or (4) provide effective 
pharmaceuticals for a sustained period of time. Before 
stent placement we propose investigation of the air-
ways with computertomography scans and bron-
choscopy in order to choose the best stent design and 
make the appropriate intervention. Finally, the type of 
lung cancer should direct us to choose the appropriate 
drug in order to invent drug eluting stents. Agents 
effective against specific types of lung cancers have 
been found, such as permetrexed for adenocarcinoma 
or TKIs for EGFR or ALK positive patients. 
 
Table 1. Stent studies (In the result section the referenced time indicates the time where the first positive results were observed.) 
Author Subject Drug Result Ref 
Chao Y.K. et. Al. animals Cisplatin with carrier 5 week with apoptosis 35 
Choong C.K. et al. animals Mitomycin C 1 week 129 
Coppit G. et. al. animals Mitomycin C No effect 130 
Sztano B.et. al.  human Mitomycin C 6 weeks 131 
Uzomefuna V. et. al.  human Mitomycin C No effect 132 
Carter J. M. et. al. human Mitomycin C Less hospitilisation days 133 
Kim H. et. al.  human Mitomycin C No effect 134 
Cardoso F.G.P. et. al. human Paclitaxel Positive effect (emphysema application) 110 
Choong C. K. et. al.  animal Paclitaxel Prolongation of patency 135 
Shah P.L.et. al. human Paclitaxel No benefit, however; safe 136 
Huvenne W. et. al. human Doxycycline Shorter healing time, less bacterial colonization, lower MMP-9 levels 36 
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Table 2. Carriers designed for coronary and airway stents. 
-Paclitaxel eluting stents 
-Sirolimus bioabsorable poly-L-lactic acid 
-Nanoporous CREGES (Sirolimus) 
-Biolimus-eluting biodegradable polymer-coated stent 
-Novel abluminal groove-filled biodegradable polymer sirolimus eluting stent 
-Doxycycline eluting stent was created from copolymer blocks 
-Polylactide-polyglycolide copolymer-cisplatin 
-Polymer-free phospholipid encapsulated sirolimus nanocarriers 
-Bioabsorbable tubular stents 
-Amphiphilic poly(ɛ-caprolactone)-poly(ethylene glycol)-poly(ɛ-caprolactone) (PCL-PEG-PCL) copolymers 
- trilayered Poly(ε-caprolactone) (PCL)-based film with a coating layer (CL), a drug-storing layer (DSL) 
 
 
 
 
Figure 3. Drug eluting stents algorithm. 
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